坎地沙坦联合氨氯地平对原发性高血压疗效分析  

Analysis of the effect of candesartan combined with amlodipine in the treatment of essential hypertension

作　　者：高兴[1] 赵玲[2] 胡玲[3] 雍雪飞[2] 周琳[3] GAO Xing;ZHAO Ling;HU Ling;YONG Xuefei;ZHOU Lin(PhaseⅠWard of Drug Clinical Trial,the Sixth People's Hospital of Chengdu,Chengdu 610051,Sichuan Province,China;Department of Nephrology,the Sixth People's Hospital of Chengdu,Chengdu 610051,Sichuan Province,China;Department of Cardiology,the Sixth People's Hospital of Chengdu,Chengdu 610051,Sichuan Province,China)

机构地区：[1]成都市第六人民医院药物临床试验Ⅰ期病房,四川成都610051 [2]成都市第六人民医院肾内科,四川成都610051 [3]成都市第六人民医院心内科,四川成都610051

出　　处：《世界临床药物》2024年第7期726-730,共5页World Clinical Drug

基　　金：四川省医学会高血压疾病(泰阁)专项科研课题(2019TG18)。

摘　　要：目的 探究坎地沙坦联合氨氯地平对原发性高血压(essential hypertension,EH)的临床疗效。方法 选取2022年2月至2023年1月我院收治的EH患者120例,按随机数字表法分为观察组(氨氯地平+坎地沙坦)与对照组(氨氯地平),每组60例,所有患者疗程均为8周。比较两组疗效、动态血压[日间收缩压变异系数(coefficient of variation in daytime systolic blood pressure,SCV)、夜间收缩压变异系数(coefficient of variation in nocturnal systolic blood pressure,nSCV)、24 h收缩压变异系数(coefficient of variation of 24-hour systolic blood pressure,24hSCV)、日间舒张压变异系数(coefficient of variation in diastolic blood pressure,DCV)、夜间舒张压变异系数(coefficient of variation in nocturnal diastolic blood pressure,nDCV)、24 h舒张压变异系数(coefficient of variation of 24-hour diastolic blood pressure,24hDCV)]、颈动脉内膜中层厚度(intimal medial thickness,IMT)、血清基质交感分子(stromal interaction molecule,STIM)1水平及不良反应发生情况等。结果 治疗后,观察组临床总有效率高于对照组(98.33% vs 80.00%),差异有统计学意义(P<0.05)。两组SCV、nSCV、24hSCV、DCV、nDCV、24hDCV、IMT、STIM1较前均降低,且观察组低于对照组(P<0.05)。两组不良反应发生率均为3.34%,差异无统计学意义(P>0.05)。结论 坎地沙坦联合氨氯地平能有效降低EH患者血压变异性、IMT及STIM1水平,改善预后,提高临床疗效。Objective To explore the clinical efficacy of candesartan combined with amlodipine on essential hypertension(EH).Methods A total of 120 EH patients admitted to our hospital from February 2022 to January 2023 were selected and divided into observation group(amlodipine+candesartan)and control group(amlodipine)according to random number table method,with 60 cases in each group.The course of treatment for all patients was 8 weeks.The efficacy,ambulatory blood pressure[coefficient of variation in daytime systolic blood pressure(SCV),coefficient of variation in nocturnal systolic blood pressure(nSCV),coefficient of variation of 24-hour systolic blood pressure(24hSCV), coefficient of variation in daytime diastolic blood pressure(DCV), coefficient of variation in nocturnaldiastolic blood pressure(nDCV), coefficient of variation of 24-hour diastolic blood pressure(24hDCV)], carotid intimalmedial thickness(IMT), stromal interaction molecule(STIM)1 and occurrence of adverse reactions of the two groupswere compared between the two groups. Results After treatment, the total clinical effective rate of the observation groupwas higher than that of the control group(98.33% vs 80.00%), the difference was statistically significant(P<0.05). SCV,nSCV, 24hSCV, DCV, nDCV, 24hDCV, IMT and STIM1 were all decreased in both groups, and the observation group waslower than the control group(P<0.05). The incidence of adverse reactions was 3.34% in both groups, with no statisticalsignificance(P>0.05). Conclusion Candesartan combined with amlodipine can effectively reduce blood pressurevariability, IMT and STIM1 levels in EH patients, improve prognosis and clinical efficacy.

关 键 词：坎地沙坦 氨氯地平 原发性高血压 血压变异性 

分 类 号：R544.11[医药卫生—心血管疾病]